{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T11:23:07Z","timestamp":1781176987610,"version":"3.54.1"},"reference-count":16,"publisher":"Cambridge University Press (CUP)","issue":"1","license":[{"start":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T00:00:00Z","timestamp":1738800000000},"content-version":"unspecified","delay-in-days":36,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["ASHE"],"published-print":{"date-parts":[[2025]]},"abstract":"<jats:title>Abstract<\/jats:title>\n\t  <jats:sec id=\"S2732494X24004418_as1\">\n\t    <jats:title>Objective:<\/jats:title>\n\t    <jats:p>Evaluate prescribing practices and risk factors for treatment failure in obese patients treated for purulent cellulitis with oral antibiotics in the outpatient setting.<\/jats:p>\n\t  <\/jats:sec>\n\t  <jats:sec id=\"S2732494X24004418_as2\">\n\t    <jats:title>Design:<\/jats:title>\n\t    <jats:p>Retrospective, multicenter, observational cohort.<\/jats:p>\n\t  <\/jats:sec>\n\t  <jats:sec id=\"S2732494X24004418_as3\">\n\t    <jats:title>Setting:<\/jats:title>\n\t    <jats:p>Emergency departments, primary care, and urgent care sites throughout Michigan.<\/jats:p>\n\t  <\/jats:sec>\n\t  <jats:sec id=\"S2732494X24004418_as4\">\n\t    <jats:title>Patients:<\/jats:title>\n\t    <jats:p>Adult patients with a body mass index of \u2265 30 kg\/m<jats:sup>2<\/jats:sup> who received \u2265 5 days of oral antibiotics for purulent cellulitis were included. Key exclusion criteria were chronic infections, antibiotic treatment within the past 30 days, and suspected polymicrobial infections.<\/jats:p>\n\t  <\/jats:sec>\n\t  <jats:sec id=\"S2732494X24004418_as5\">\n\t    <jats:title>Methods:<\/jats:title>\n\t    <jats:p>Obese patients receiving oral antibiotics for purulent cellulitis between February 1, 2020, and August 31, 2023, were assessed. The primary objective was to describe outpatient prescribing trends. Secondary objectives included comparing patient risk factors for treatment failure and safety outcomes between patients experiencing treatment success and those experiencing treatment failure.<\/jats:p>\n\t  <\/jats:sec>\n\t  <jats:sec id=\"S2732494X24004418_as6\">\n\t    <jats:title>Results:<\/jats:title>\n\t    <jats:p>Two hundred patients were included (Treatment success, n = 100; Treatment failure, n = 100). Patients received 11 antibiotic regimens with 26 dosing variations; 45.5% were inappropriately dosed. Sixty-seven percent of patients received MRSA-active therapy. Treatment failure was similar between those appropriately dosed (46.4%) versus under-dosed (54.4%) (<jats:italic>P<\/jats:italic> = 0.256), those receiving 5\u20137 days of therapy (47.1%) versus 10\u201314 days (54.4%) (<jats:italic>P<\/jats:italic> = 0.311), and those receiving MRSA-active therapy (52.2%) versus no MRSA therapy (45.5%) (<jats:italic>P<\/jats:italic> = 0.367). Patients treated with clindamycin were more likely to experience treatment failure (73.7% vs 47.5%, <jats:italic>P<\/jats:italic> = 0.030).<\/jats:p>\n\t  <\/jats:sec>\n\t  <jats:sec id=\"S2732494X24004418_as7\">\n\t    <jats:title>Conclusions:<\/jats:title>\n\t    <jats:p>Nearly half of antimicrobial regimens prescribed for outpatient treatment of cellulitis in patients with obesity were suboptimally prescribed. Opportunities exist to optimize agent selection, dosing, and duration of therapy in this population.<\/jats:p>\n\t  <\/jats:sec>","DOI":"10.1017\/ash.2024.441","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T06:51:08Z","timestamp":1738824668000},"source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of prescribing practices and treatment failure for purulent skin and soft tissue infections in patients with obesity"],"prefix":"10.1017","volume":"5","author":[{"given":"Mackenzie L.","family":"Miller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Destiny M.","family":"Hughson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9039-3213","authenticated-orcid":false,"given":"Noah D.","family":"Blower","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0017-6906","authenticated-orcid":false,"given":"Andrew P.","family":"Jameson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1416-357X","authenticated-orcid":false,"given":"Lisa E.","family":"Dumkow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2025,2,6]]},"reference":[{"key":"S2732494X24004418_ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055356"},{"key":"S2732494X24004418_ref13","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01453-12"},{"key":"S2732494X24004418_ref8","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz002"},{"key":"S2732494X24004418_ref1","volume-title":"Pharmacotherapy: A Pathophysiologic Approach","author":"Fish","year":"2022"},{"key":"S2732494X24004418_ref6","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASM.0001016824.34963.fd"},{"key":"S2732494X24004418_ref11","unstructured":"11. Clindamycin (Systemic). Lexi-Drugs. UpToDate Lexidrug. UpToDate Inc; 2024. https:\/\/online.lexi.com. Accessed June 21, 2024"},{"key":"S2732494X24004418_ref14","doi-asserted-by":"publisher","DOI":"10.1046\/j.1469-0691.2001.00061.x"},{"key":"S2732494X24004418_ref3","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2769"},{"key":"S2732494X24004418_ref4","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01719-23"},{"key":"S2732494X24004418_ref2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv189"},{"key":"S2732494X24004418_ref12","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/261519"},{"key":"S2732494X24004418_ref7","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu444"},{"key":"S2732494X24004418_ref5","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12200"},{"key":"S2732494X24004418_ref9","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00377-07"},{"key":"S2732494X24004418_ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.12.004"},{"key":"S2732494X24004418_ref16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2009.02906.x"}],"container-title":["Antimicrobial Stewardship &amp; Healthcare Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S2732494X24004418","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T06:51:11Z","timestamp":1738824671000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S2732494X24004418\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025]]}},"alternative-id":["S2732494X24004418"],"URL":"https:\/\/doi.org\/10.1017\/ash.2024.441","relation":{},"ISSN":["2732-494X"],"issn-type":[{"value":"2732-494X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"e31"}}